TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ).
Hansoh Pharmaceutical Group Company Limited announced that two new indications of its drug Ameile have been added to the 2025 National Reimbursement Drug List (NRDL), while all indications of its drugs Saint Luolai and Hengmu have been renewed. This inclusion, effective January 1, 2026, signifies a strategic advancement for Hansoh, potentially enhancing its market share and accessibility of its innovative treatments for non-small cell lung cancer, anemia in chronic kidney disease, and chronic hepatitis B.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$47.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company based in the Cayman Islands, focusing on innovative drug development. The company specializes in treatments for cancer, chronic kidney disease, and hepatitis B, among other conditions, and aims to enhance its market presence through inclusion in national drug reimbursement lists.
Average Trading Volume: 9,289,513
Technical Sentiment Signal: Buy
Current Market Cap: HK$254B
Learn more about 3692 stock on TipRanks’ Stock Analysis page.